Pharmaceutical companies and payers increasingly engage in value-based pricing agreements, which link payment for a medicine to value achieved. However, the traditional approach to drug development has been oriented towards efficacy and safety and is unable to address the evidence requirements from payers and health technology assessors. To support this emerging paradigm change in drug development, Archimedes has developed a systematic framework that integrates evidence (randomized clinical trials, electronic medical records, claims, laboratory results, disease registries) with analytics and modeling (predictive modeling, health-economic simulation, cost-effectiveness analysis) to provide a comprehensive assessment of all health and economic benefits of new interventions – including potential cost savings elsewhere in the treatment pathways, improvements in quality of life of patients and caregivers as well as other societal benefits. The framework  leverages the strength of the Archimedes ARCHES Simulation platform as well as a suite of analytic tools and services developed specifically to capture values of interventions. It also enables probabilistic sensitivity analysis and uncertainty quantification of predicted values. The framework is designed to integrate organically with the life-cycle of product development. It will help the pharmaceutical companies to establish the value-based evidence-generation process, identify subpopulations for which their medications are most valuable, and evaluate commercial value of new medications as early as possible in the development cycle. In this presentation, we will present the key elements of the framework as well as the results of a case study, in which the framework is used to support value-based pricing for a novel intervention. We will demonstrate how costs and benefits of the intervention vary across different subpopulations, suggesting a multi-tiered pricing approach may be the optimal strategy for the intervention.